Quoin's QRX003 Hits Primary Endpoint in Phase 2/3 Netherton Syndrome Trial
QNRX has more than doubled off its 52-week low of $3.25 on light trading volume (0.1× avg).
Summary
Quoin Pharmaceuticals reported positive interim data from its ongoing Phase 2/3 study of QRX003 in Netherton Syndrome. The primary endpoint was met with statistical significance: 4 of 6 patients (66.7%) achieved a 1-grade or greater improvement in IGA at Week 12 (p=0.0087 vs α=0.0215). A key secondary endpoint, Global Impression of Change, also reached significance (p=0.007). No treatment-related serious adverse events were reported. The company expects to complete recruitment of all 20 participants by end of 2026 and report topline data in Q2 2027. This is the first efficacy data from the pivotal study and supports the drug's potential as the first FDA-approved treatment for Netherton Syndrome. The results follow prior positive compassionate use data and multiple regulatory designations, reinforcing the clinical profile. Given the company's small market cap and going concern status, this positive interim readout is a significant de-risking event for the lead asset.
At the time of this announcement, QNRX was trading at $8.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $3.25 to $41.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.